THURSDAY, Sept. 12, 2024 -- The overall second primary malignancy (SPM) point estimate was 5.8 percent for patients receiving chimeric antigen...
Vous n'êtes pas connecté
Mayo Clinic researchers mined the molecular foundations of cancer and uncovered a new reason chimeric antigen receptor (CAR-T cell therapy) fails in some patients.
THURSDAY, Sept. 12, 2024 -- The overall second primary malignancy (SPM) point estimate was 5.8 percent for patients receiving chimeric antigen...
Researchers at the University of Michigan Health Rogel Cancer Center, USA, have uncovered a key reason why a typically normal protein goes awry and...
Advanced treatments like CAR-T cell therapy and bone marrow transplants are significantly improving outcomes for lymphoma patients, experts highlight...
Highlights: Secondary Primary Malignancy rates did not significantly differ among various CAR T-cell therapies or c
Highlights: Secondary Primary Malignancy rates did not significantly differ among various CAR T-cell therapies or c
Learn why the FDA has mandated boxed warnings for CAR T-cell therapies, highlighting the risks of secondary malignancies.
62% of patients currently receiving treatment for depression-amounting to a staggering 5.1 to 5.6 million individuals-could qualify for psilocybin...
WEDNESDAY, Sept. 11, 2024 -- Contrary to a warning placed on labels for CART-T cancer therapies, use of these treatments does not appear to boost the...
Researchers at the National Institute of Biology are exploring new avenues for more effective treatment of glioblastoma, the most aggressive form of...
Researchers at the University of Michigan Health Rogel Cancer Center have uncovered a key reason why a typically normal protein goes awry and fuels...